176 related articles for article (PubMed ID: 16777663)
41. omega-3 Fatty acid for schizophrenia.
Horrobin DF
Am J Psychiatry; 2003 Jan; 160(1):188-9; author reply 189. PubMed ID: 12505833
[No Abstract] [Full Text] [Related]
42. [Possible involvement of phospholipase A2 in the pathogenesis of schizophrenia].
Gattaz WF; Nevalainen TJ; Kinnunen PK
Fortschr Neurol Psychiatr; 1990 Apr; 58(4):148-53. PubMed ID: 2354835
[TBL] [Abstract][Full Text] [Related]
43. Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages.
Kobayashi J; Yokoyama S; Kitamura S
Prostaglandins Leukot Essent Fatty Acids; 1995 Apr; 52(4):259-62. PubMed ID: 7784475
[TBL] [Abstract][Full Text] [Related]
44. [Against: is monotherapy the gold standard of psychopharmacology?].
Bechter K
Psychiatr Prax; 2006 Jul; 33(5):208-10. PubMed ID: 16874937
[No Abstract] [Full Text] [Related]
45. Stabilization of synaptic membranes by alpha-tocopherol against the damaging action of phospholipases. Possible mechanism of biological action of vitamin E.
Erin AN; Gorbunov NV; Brusovanik VI; Tyurin VA; Prilipko LL
Brain Res; 1986 Nov; 398(1):85-90. PubMed ID: 3801901
[TBL] [Abstract][Full Text] [Related]
46. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid.
Richardson AJ; Easton T; Puri BK
Eur Neuropsychopharmacol; 2000 May; 10(3):189-93. PubMed ID: 10793321
[TBL] [Abstract][Full Text] [Related]
47. What synaptic lipid signaling tells us about seizure-induced damage and epileptogenesis.
Bazan NG; Tu B; Rodriguez de Turco EB
Prog Brain Res; 2002; 135():175-85. PubMed ID: 12143339
[TBL] [Abstract][Full Text] [Related]
48. Phospholipase A2 and its role in brain tissue.
Farooqui AA; Yang HC; Rosenberger TA; Horrocks LA
J Neurochem; 1997 Sep; 69(3):889-901. PubMed ID: 9282910
[TBL] [Abstract][Full Text] [Related]
49. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes.
Puri BK; Richardson AJ; Horrobin DF; Easton T; Saeed N; Oatridge A; Hajnal JV; Bydder GM
Int J Clin Pract; 2000; 54(1):57-63. PubMed ID: 10750263
[TBL] [Abstract][Full Text] [Related]
50. Effect of chronic ethanol exposure on mouse brain arachidonic acid specific phospholipase A2.
Basavarajappa BS; Cooper TB; Hungund BL
Biochem Pharmacol; 1998 Feb; 55(4):515-21. PubMed ID: 9514087
[TBL] [Abstract][Full Text] [Related]
51. [Oxidative stress involvement in schizophrenia pathophysiology: a review].
Fendri C; Mechri A; Khiari G; Othman A; Kerkeni A; Gaha L
Encephale; 2006; 32(2 Pt 1):244-52. PubMed ID: 16910626
[TBL] [Abstract][Full Text] [Related]
52. [Neuronal plasticity of schizophrenia].
Crocq MA
Encephale; 2007 Jun; 33 Pt 3():S402-7. PubMed ID: 19101360
[No Abstract] [Full Text] [Related]
53. Increased platelet phospholipase A2 activity in schizophrenia.
Gattaz WF; Schmitt A; Maras A
Schizophr Res; 1995 Jul; 16(1):1-6. PubMed ID: 7547640
[TBL] [Abstract][Full Text] [Related]
54. Modulation of synaptic GABA receptor binding by membrane phospholipids: possible role of active oxygen radicals.
Yoneda Y; Kuriyama K; Takahashi M
Brain Res; 1985 Apr; 333(1):111-22. PubMed ID: 2986768
[TBL] [Abstract][Full Text] [Related]
55. Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells.
Fonteh AN; Bass DA; Marshall LA; Seeds M; Samet JM; Chilton FH
J Immunol; 1994 Jun; 152(11):5438-46. PubMed ID: 8189063
[TBL] [Abstract][Full Text] [Related]
56. Somatostatin inhibition of hippocampal CA1 pyramidal neurons: mediation by arachidonic acid and its metabolites.
Schweitzer P; Madamba S; Champagnat J; Siggins GR
J Neurosci; 1993 May; 13(5):2033-49. PubMed ID: 8097529
[TBL] [Abstract][Full Text] [Related]
57. Postsynaptic injection of calcium-independent phospholipase A2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission.
St-Gelais F; Ménard C; Congar P; Trudeau LE; Massicotte G
Hippocampus; 2004; 14(3):319-25. PubMed ID: 15132431
[TBL] [Abstract][Full Text] [Related]
58. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations.
Tessier C; Sweers K; Frajerman A; Bergaoui H; Ferreri F; Delva C; Lapidus N; Lamaziere A; Roiser JP; De Hert M; Nuss P
Transl Psychiatry; 2016 Oct; 6(10):e906. PubMed ID: 27701405
[TBL] [Abstract][Full Text] [Related]
59. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.
Schaeffer EL; Forlenza OV; Gattaz WF
Psychopharmacology (Berl); 2009 Jan; 202(1-3):37-51. PubMed ID: 18853146
[TBL] [Abstract][Full Text] [Related]
60. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients.
Arvindakshan M; Sitasawad S; Debsikdar V; Ghate M; Evans D; Horrobin DF; Bennett C; Ranjekar PK; Mahadik SP
Biol Psychiatry; 2003 Jan; 53(1):56-64. PubMed ID: 12513945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
